Mastek Q1 FY27 Earnings Call — Analysis (NSE: MASTEK)

Strong order book momentum with $310M 12-month backlog and a landmark $25M AI deal in North America, but Middle East geopolitical uncertainty and ESOP costs weigh on near-term margins.

28 Jul 2026 · Analysis by Alpha Inflection

The take

Q1FY27 Revenue (INR) ₹985 Cr ( +5% QoQ ) . New guidance — north america business margin a… mid-teens . New story: AI-led transformation positioning .

Results

Revenue ₹985 Cr +5% QoQ (+7.7% YoY); EBITDA at 15.4% impacted by Middle East bench costs and delayed collections; PAT ₹105.9 Cr; 12-month order backlog $310M +13.3% YoY.

Financial highlights

Guidance

FY27 performance expected to be better than FY26; North America anticipated to become a growth engine by H2FY27 and deliver mid-teens EBITDA margins upon reaching $28–30M quarterly run rate.

What management committed to

• [The $25M AI transformation deal in Salesforce Agentforce won in North America] is expected to ramp up by H2FY27. — H2FY27
• As [North America business] reaches close to $28 million to $30 million a quarter run rate, [North America business] will start delivering healthy margins of somewhere around mid-teens. — mid-teens
• [Mastek's] FY27 performance should be better than FY26. — FY27
• As we get into Q2 and beyond, [UK Healthcare business / NHS England] should be able to get back to usual performance and growth. — Q2FY27
• ESOP grant impact [on Mastek's P&L] is estimated at $400,000 to $500,000 per quarter [starting Q2FY27]. — $400,000 to $500,000 per quarter, Q2FY27
• [Mastek] has increment planned in Q2[FY27]. — Q2FY27
• [Mastek is] definitely working on internal cost efficiencies to basically mitigate a significant portion of the impact [of ESOP costs and salary increments on EBITDA]. — significant portion
• [North America] will take at least H2 of this year [FY27] to turn itself into a growth engine. — H2FY27
• [Mastek is] quite sure that [its] Healthcare Life Sciences business in the U.S. is also going to be ramped up [by H2FY27]. — H2FY27
• If [the geopolitical situation in Middle East] stabilise[s], [Mastek] should be able to actually move back to growth in Middle East.

Key themes

AI transformation pivot amid geopolitical headwinds

How the narrative shifted

• AI-led transformation positioning: Management positions Mastek as uniquely capable of becoming an AI transformation company in healthcare and public sector, leveraging its enterprise apps, data, and engineering practices.
• UK business as stable growth foundation: UK business (public sector, healthcare, BFS) framed as the reliable core delivering consistent growth, with BFS now converting order book into revenue and public sector staying resilient.
• North America turnaround underway: Three consecutive quarters of strong order book framed as evidence of a sustained turnaround; large $25M AI deal as validation; H2FY27 positioned as the inflection point for growth and margin.
• Middle East geopolitical headwinds: West Asia crisis creating instability and unpredictability; holding bench in anticipation of ramp-ups that keep getting delayed; conditional recovery tied to geopolitical stabilisation.
• Margin management with ESOP and investments: ESOP and increments as necessary long-term investments in leadership stability and transformation; cost efficiencies being pursued to mitigate near-term EBITDA impact; no firm margin guidance given.
• Healthcare modernisation cycle: NHS England transitioning from legacy projects to data-modernisation and data-platform work; US Healthcare Life Sciences being built as key vertical; Middle East healthcare pipeline strong but timing uncertain.
• Internal business transformation as Customer Zero: Mastek deploying AI-native Service-as-a-Software internally to replace core systems, creating case studies for clients and shifting workforce to forward-deployed engineering/consulting model.
• Champion challenger competitive strategy: Targeting net-new accounts where incumbents face pricing pressure; competing aggressively on price while aiming to execute better on fixed-bid or outcome-focused contracts to preserve margin.
• Public sector political transition risk (UK): UK political leadership change being closely monitored for policy and budget priority shifts; cost-saving demand remains high, which Mastek can address but macro risk acknowledged.
• Aggressive price competition in renewals and new wins: Discounts of 15–20% common in renewals, net-new deals coming at more aggressive pricing; management believes fixed-bid and outcome-focused execution can offset pricing pressure.

Operational commentary

• Won $25M AI transformation deal (Salesforce Agentforce) in North America — one of the largest deals in recent quarters, 5-year term.
• North America achieved strong order book for third consecutive quarter; total backlog up 29.8% QoQ and 23.5% YoY.
• Closed 40+ AI-led new opportunities in Q1 across existing and new accounts, spanning AI governance/security, use-case adoption, and enterprise-wide transformation.
• UK Banking & Financial Services growth driven by FCA deal ramp-up; further ramp-up expected in Q2FY27.
• NHS England (UK Healthcare) undergoing project transition: old projects ramping down, new data-modernisation and data-platform projects starting; sequential growth expected from Q2FY27.
• Middle East: large healthcare deal closed in Q1 and more in advanced pipeline, but geopolitical volatility in West Asia creates uncertainty around ramp-up timelines and collections.
• COO Amit Gajwani appointed — joined from LTM with mandate to transform delivery governance, talent pool, and shift organisation toward outcome-focused execution.
• Internal AI business transformation launched (Mastek as Customer Zero) — replaced core systems (CRM, recruitment, payables) with AI-native solutions; positioned as Service-as-a-Software case studies for clients.
• UK Public Sector stable and growing sequentially; monitoring new government's policy and budget priorities closely as political leadership changes.

Analyst Q&A

• Q. When do FCA, Atlas, HADES, and US deals ramp up?

  FCA already ramping, more in Q2; HADES is a renewal with steady revenue; North America $25M deal ramping by H2FY27.

• Q. How have TCV trends been and are you seeing irrational discounting?

  TCV moving in right direction — 5-year $25M deal indicative; discounting at 15–20% generally, up to 25% in isolated cases, not 50%.

• Q. Excluding the $25M deal, order backlog appears flat sequentially — how do you see pipeline and funnel?

  Pipeline improving across geographies; large-deal opportunities increasing; AI-led mid-to-large land-and-expand deals growing; Middle East closed large healthcare deal but current volatility may slow ramp-ups.

• Q. What is the steady-state EBITDA margin once ESOP costs are included?

  No guidance at this point; working on internal cost efficiencies to mitigate significant portion of ESOP and increment impact; long-term ESOP aligns team for better outcomes.

• Q. Can QoQ improvement continue beyond Q1 or are there headwinds?

  UK confident to deliver; North America needs 1–2 more good quarters, expects H2 turnaround; Middle East uncertain; FY27 should be better than FY26.

• Q. What changed so significantly this quarter versus last quarter's subdued commentary?

  Business trending in similar direction as Q4; order backlog consistently growing into execution; AI initiatives picking up more but not a drastic shift; confidence from sustained order book build.

View source

Research and educational content only. Not investment advice.